The Role of the Selective Serotonin Re-Uptake Inhibitor Sertraline in Nondepressive Patients with Chronic Ischemic Heart Failure: A Preliminary Study
Authors:
- Dionyssios LeftheriotisDLDionyssios Leftheriotis
- Ignatios IkonomidisIgnatios Ikonomidis
- Lefteris LykourasLLLefteris Lykouras
- Dimitrios Th. KremastinosDKDimitrios Th. Kremastinos
- 11 May 2010
- journal article
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 33 (10) , 1217-1223
Abstract
Background: Selective serotonin re-uptake inhibitors (SSRIs) have been associated with better psychiatric status, functional capacity, and fewer arrhythmias in depressive patients with heart failure (HF). In this study, we tested the impact of sertraline (an SSRI) on patients with HF, but not clinical depression. Methods: We studied 62 clinically stable, nondepressive patients with ischemic HF (New York Heart Association class: I-II), and implantable cardioverter-defibrillator (ICD). Following psychiatric evaluation and quality of life (QoL) assessment, 24-hour electrocardiogram recordings including heart rate variability (HRV) and ICD interrogation were performed every 4 months for 1 year. Ventricular effective refractory period (ERP) at 600-, 500-, and 400-ms cycle length and the inducibility of ventricular tachycardia (VT) were assessed via the ICD. After that, sertraline 50 mg/day was administered for 12 months and the whole evaluation was repeated. Results: Sertraline was associated with fewer ventricular extrasystoles per 24 hours and a significant change in HRV (increase in mean R-R, 5-minute standard deviation of RR intervals, and root mean-square difference of successive RR intervals, and reduction in ultra and very low frequency). It was also followed by an improvement in patients’ QoL. A trend toward a decrease was observed in the number of recalled nonsustained VTs. The episodes of sustained VT were not significantly reduced. Ventricular ERPs and VT inducibility remained unaltered. Conclusion: In clinically stable, nondepressive patients with ischemic HF and ICD, sertraline is associated with reduced ventricular extrasystoles, better QoL, and a possible improvement in some HRV indexes. This suggests that SSRIs may have a favorable clinical impact on these patients, independent of the improvement in depressive symptoms. (PACE 2010; 33:1217–1223)Keywords
This publication has 40 references indexed in Scilit:
- Antidepressant Use, Depression, and Survival in Patients With Heart FailureArchives of internal medicine (1960), 2008
- Depression and ischemic heart disease: what have we learned from clinical trials?Current Opinion in Cardiology, 2007
- Effects of Citalopram and Interpersonal Psychotherapy on Depression in Patients With Coronary Artery DiseaseJAMA, 2007
- 5-Hydroxytryptamine receptors in the human cardiovascular systemPharmacology & Therapeutics, 2006
- Usefulness of Paroxetine in Depressed Men With Paroxysmal Atrial FibrillationThe American Journal of Cardiology, 2006
- Depression and ischemic heart disease: What have we learned so far and what must we do in the future?American Heart Journal, 2005
- Involvement of the Serotonin 5-HT 2B Receptor in Cardiac Hypertrophy Linked to Sympathetic StimulationCirculation, 2004
- Functional Consequence of Serotonin/5-HT 2B Receptor Signaling in HeartCirculation, 2003
- Effect of treatment of panic disorder in patients with frequent ICD discharges: a pilot studyGeneral Hospital Psychiatry, 2002
- How Safe Are Serotonin Reuptake Inhibitors for Depression in Patients with Coronary Heart Disease?The American Journal of Medicine, 1997